Changes associated to the DR3DQ2 haplotype
Comparison of the immune response in individuals who received GAD-alum stratified according to the DR3DQ2 haplotype showed that GADImmune response from day 1 to 15 months in GAD-alum treated patients with (black, n=29) and without (light blue, n=27) DR3DQ2 haplotype. 